


Claims

1. A compound of Formula (I)



Formula (I)

or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein:

Y is NR ;

(i) R is hydrogen;

R_2 and R_{3a} in combination with the pyrimidine ring of formula (I) form an unsubstituted pyrrolo[2,3-d]pyrimidine ring;

R_1 is hydrogen;

R_{4a} is C_{1-4} haloalkyl;

R_{4b} is selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_1 - C_4 alkoxy, and C_{1-4} haloalkoxy;

R_5 is $-(CR_8R_9)_p-CR_{13}R_{14}R_{15}$;

n and p are 0;

R_{6a} is hydrogen;

R_{6b} is hydrogen;

R_8 and R_9 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl- C_{1-6} alkyl, heteroaryl- C_{1-6} alkyl, and aryl;

R_{13} is absent;

R_{14} and R_{15} are combined to form a C_{6-12} membered aryl;

B is 6-membered aryl;

R_{3b} is hydrogen; and

R_{3c} is hydrogen.

2. The compound according to claim 1, wherein R_{14} and R_{15} are combined to form a ring system selected from the group consisting of phenyl and naphthyl.

3. The compound according to claim 2 wherein the ring system is phenyl.

4. The compound according to claim 2 or 3, wherein the ring system formed by the combination of R_{14} and R_{15} is substituted with one or more $-(CH_2)_q(R_{5a})$ wherein R_{5a} is $-CH_2CONR_{21}R_{22}$;

R_{21} and R_{22} are hydrogen; and

q is 0.

5. The compound according to any one of claims 2 to 4, wherein the ring system formed by the combination of R_{14} and R_{15} is substituted with one $-CH_2CONH_2$.

6. The compound according to any one of claims 1 to 5, wherein R_{4a} is C_{1-2} haloalkyl.


7. The compound according to any one of claims 1 to 6, wherein R_{4a} is selected from the group consisting of $-CF_3$ and $-CHF_2$.

8. The compound according to any one of claims 1 to 7, wherein R_{4a} is $-CF_3$.

9. The compound according to any one of claims 1 to 8 wherein ring system B is a 6-membered aryl ring having R_{4a} in the *para*-position or *meta*-position.

10. The compound according to any one of claims 1 to 9, wherein ring system B is a phenyl.

11. The compound according to claims 1 to 10, wherein the compound of formula (I) has the formula (IIab)



Formula (IIab)

wherein R_{4e} and R_{4d} are hydrogen.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 and at least one pharmaceutical acceptable excipient.

13. A compound according to any one of claims 1 to 11 or pharmaceutical composition according to claim 12, for use in therapy.

14. A compound according to any one of claims 1 to 11 or pharmaceutical composition according to claim 12, for use in the treatment and/or prevention of inflammatory, metabolic and autoimmune diseases or disorders.

15. A compound according to any one of claims 1 to 11 or pharmaceutical composition according to claim 12, for use in the treatment and/or prevention of a disease or disorder selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, sprue and food allergy, atopic dermatitis, cystic fibrosis, lung allograft rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (IBD),

inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, Guillain-Barre syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance and type II diabetes, and cancer.

16. A compound according to any one of claims 1 to 11 or pharmaceutical composition according to claim 12, for modulating the activity of a retinoic acid receptor-related orphan receptor (ROR).

17. A compound or pharmaceutical composition according to claim 16, wherein the receptor is a ROR γ receptor.

18. A compound or pharmaceutical composition according to claim 16 or claim 17, wherein the receptor is a ROR γ 1 or ROR γ t receptor.

19. A compound or pharmaceutical composition according to claim 16, wherein the compound or pharmaceutical composition modulates the activity of an ROR γ receptor to a larger extent than it modulates the activity of ROR α and/or ROR β receptors.